2025 FDA approvals CDER Brings Many Safe and Effective Therapies to Patients and Consumers in 2024 FDA FDA Action Update, January 2026: Approvals, Acceptance, and Clearance NeurologyLive Clinical Neurology News and Neurology Expert Insights FDA Category 2 Update: The 5 Peptides Still Facing Heavy Review As excitement builds around peptides potentially moving off the FDA Category 2 list, it's important to understand one key reality: Not DHX PNB 0408 Pure Health Peptides The FDA's Current Position on Peptides Explained Holt Law